Please assess the completion status of the following clinical trial:

Trial Title: TaxoteRe Plus Cisplatin Versus AlImta Plus Cisplatin in 1st Line Non-squamous Cell Type Lung Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age \>= 18 years old~* ECOG performance status 0-2~* Non-squamous cell type non-small cell lung cancer (NSCLC)~* Stage IV, Stage IIIB cannot be treated with curative intent or Relapsed after surgery or radiation therapy~* No prior chemotherapy except adjuvant chemotherapy and concurrent chemoradiation treatment. The last dose of adjuvant chemotherapy should be at least 6 months earlier from randomization, and the regimen should not contain docetaxel or pemetrexed.~* No prior immunotherapy, biologic therapy~* Measurable lesion with Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1~* Hemoglobin \>=9.0g/dl, Platelet \>=100,000/uL, neutrophil \>=1,500 /uL Creatinine \<=1.5 x upper normal limit or creatinine clearance \>=60 mL/min Bilirubin \<=1.5 x upper normal limit, Transaminases \<=2 x upper normal limit Alkaline phosphatase \<=2 x upper normal limit~* Written informed consent~Exclusion Criteria:~* Pregnancy, Lactating woman~* Woman in child bearing age who refuses to do pregnancy test~* Moderate or greater than grade 1 motor or sensory neurotoxicity~* Hypersensitivity to taxane~* Comorbidity or poor medical conditions~* Other malignancy (except cured basal cell carcinoma or uterine cervical carcinoma in situ)~* Concurrent treatment with other investigational drugs within 30 days before randomization~* Active treatment with other anticancer chemotherapy~* EGFR mutation (exon 19 deletion, L858R, L861Q, G719A/C/S)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Taxotere (Type: EXPERIMENTAL): Docetaxel plus Cisplatin
- Pemetrexed (Type: ACTIVE_COMPARATOR): Pemetrexed plus Cisplatin

Based on this trial design, predict the completion outcome and termination type (if applicable).